SHERPA™ Bioinformatics Engine

Systematic HLA Epitope Ranking

Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails the comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Personalis’ ImmunoID NeXT™ enables a comprehensive survey of putative neoantigens by combining highly sensitive exome scale DNA and RNA sequencing with advanced analytics. Personalis developed the Systematic HLA Epitope Ranking Pan Algorithm (SHERPA) to predict MHC class I binding and presentation and to identify potentially Immunogenic patient-specific neoantigens.